Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
RegenXBio Inc. (RGNX)
:RGNX
Holding RGNX?
Track your performance easily
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-1.13Last Year’s EPS
-1.43Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2018
|% Change Since: -24.18%
|Next Earnings Date:Aug 08, 2018
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in REGENXBIO's gene therapy programs with upcoming milestones, indicating strong progress in the pipeline. However, there were decreases in R&D expenses and cash, reflecting some financial challenges.Company Guidance
During the Q3 2024 earnings call for REGENXBIO, several key metrics and guidance were provided. The company reported cash, cash equivalents, and marketable securities totaling $279 million as of September 30, 2024, with expectations to fund operations into 2026. Research and development expenses for the quarter were $54 million, down from $58 million in the same period the previous year. The guidance highlighted several upcoming milestones, including the initiation of a pivotal trial for RGX-202, expected to begin imminently, and the completion of the End-of-Phase II meeting with the FDA for RGX-314 in diabetic retinopathy within Q4 2024. Additionally, the first module of a rolling BLA for RGX-121 was submitted as planned, with completion anticipated in Q1 2025. The company also pointed out potential financial impacts not included in their guidance, such as payments from AbbVie for milestone achievements and the potential monetization of a Priority Review Voucher for RGX-121.Advancements in Gene Therapy Programs
REGENXBIO has made significant progress in several gene therapy programs, including RGX-202 for Duchenne, RGX-121 for MPS II, and RGX-314 for wet AMD and DR. Key milestones include the initiation of BLA filing for RGX-121 and upcoming pivotal trials.
First Functional Data for Duchenne Program
The company expects to share the first functional data from the Duchenne program later this month, marking a significant step in its development.
Strong Financial Position
REGENXBIO ended the quarter with $279 million in cash, cash equivalents, and marketable securities, expected to fund operations into 2026.
Positive Data from Retinal Studies
RGX-314 for wet AMD showed a 97% reduction in treatment burden at 9 months, with 100% of patients needing 0 or 1 supplemental injections.
---
RGNX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RGNX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $9.43 | $11.19 | +18.66% |
| Aug 01, 2024 | $13.31 | $13.04 | -2.03% |
| May 08, 2024 | $16.67 | $15.68 | -5.94% |
| Feb 27, 2024 | $20.02 | $19.90 | -0.60% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does RegenXBio Inc. (RGNX) report earnings?
RegenXBio Inc. (RGNX) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is RegenXBio Inc. (RGNX) earnings time?
RegenXBio Inc. (RGNX) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RGNX EPS forecast?
RGNX EPS forecast for the fiscal quarter 2024 (Q4) is -1.13.
---